ArticleAdvanced biomedical research2024
Does Gabapentin Have A Role in the Improvement of Feeding Resistance in Infants?
Article in Advanced biomedical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eating disorders in some infants can be due to the inability to reach a level of relaxation necessary to start the feeding process. Gabapentin (GB) has been proposed as a stabilizer of nerve function in improving this disorder. This study aimed to investigate the effect of GB on improving feeding resistance in infants aged 3-6 months. Materials and Methods: This randomized, controlled, double-blind clinical trial was done on 64 infants aged 3-6 months with feeding resistance who were referred to the pediatric clinics and assigned to two groups of 32. The case group was given a dose of 5 mg/kg of GB in the first week, and if not too much sedation, it was increased to 10 mg/kg in the second week every 8 hours, whereas the control group received a placebo. The number of effective breastfeeding and the volume of formula in cc before and after 2 weeks of drug usage were recorded in both groups. Results: The number of breastfeeding sessions significantly had a higher increase in the GB group compared with placebo (median [IQR]: 1 [0,1] vs. 0 [0,1], Conclusion: Considering the significant increase in formula consumption and the number of breastfeeding sessions in the GB group, it is possible to use this drug as a nerve-stabilizer and pain reducer to treat this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.